InsidersTradesSigma
Track the ACCURAY INC stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, ACCURAY INC has recorded 154 insider filings. Market capitalisation: €28.7m. The latest transaction was disclosed on 1 April 2026 (Retenue fiscale). Among the most active insiders: Pervaiz Ali. All data is openly available.
154
Insider Decl.
n/a
Thresholds
€416,993
11 ops.
Buy Volume
€1m
46 ops.
Sell Volume
34Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 25,457 of 29,064 companies
24.5
score / 100
Value29
Quality20
FCF yld-20%
Earn yld-5.5%
EV/EBITDA10.1x
ROE-101%
Gross mgn32%
Net mgn-0.3%
Debt/EBITDA8.7x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 1 April 2026
Declarations154 total
40,000 shares@ US$0.38814.4% of flowCommon StockSEC:0001214659-26-004180:0
28,969 shares@ US$0.55100.0% of flowCommon StockSEC:0001214659-26-002732:1
83,723 shares0Common StockSEC:0001214659-26-002732:0
54,875 shares@ US$0.562731.6% of flowCommon StockSEC:0001214659-26-002305:0
Canonical exit: 21 May 2026 (T+90)
126,125 shares@ US$0.532868.4% of flowCommon StockSEC:0001214659-26-002238:0
Canonical exit: 19 May 2026 (T+90)
9,433 shares0Common StockSEC:0001214659-26-000329:0
64,477 shares@ US$1.0219.3% of flowCommon StockSEC:0001214659-25-017523:1
57,341 shares@ US$1.0222.3% of flowCommon StockSEC:0001214659-25-017524:1
895,391 shares0Common StockSEC:0001214659-25-017519:0
50,000 shares0Common StockSEC:0001214659-25-017520:0
50,314 shares0Common StockSEC:0001214659-25-017523:0
44,025 shares0Common StockSEC:0001214659-25-017524:0
22,642 shares@ US$1.053.8% of flowCommon StockSEC:0001214659-25-017242:1
22,642 shares@ US$1.053.2% of flowCommon StockSEC:0001214659-25-017246:1
56,603 shares0Common StockSEC:0001214659-25-017241:0
56,603 shares0Common StockSEC:0001214659-25-017242:0
56,603 shares0Common StockSEC:0001214659-25-017243:0
45,620 shares0Common StockSEC:0001214659-25-017244:0
56,603 shares0Common StockSEC:0001214659-25-017245:0
56,603 shares0Common StockSEC:0001214659-25-017246:0
56,603 shares0Common StockSEC:0001214659-25-017247:0
20,000 shares@ US$0.9705100.0% of flowCommon StockSEC:0001214659-25-016957:0
Canonical exit: 17 Feb 2026 (T+90)
56,603 shares0Common StockSEC:0001214659-25-016848:0
354,609 shares0Common StockSEC:0001214659-25-015795:0
37,500 shares0Common StockSEC:0001214659-25-015796:0
25 of 154 declarations
关于 ACCURAY INC
Accuray Incorporated（股票代码：ARAY）是一家在美国纳斯达克上市的美国医疗技术公司，专注于用于癌症治疗和神经外科放射外科的精密放射治疗系统。Accuray 总部位于威斯康星州麦迪逊，将自己定位为先进放射肿瘤学解决方案的差异化提供商，旨在为寻求针对复杂病例进行高度靶向治疗并简化标准工作流程的医院和治疗中心提供服务。对于股票投资者而言，这使得该公司明确属于医疗保健设备子行业，面临临床采用周期、供应商的资本采购决策以及管理医疗设备的监管环境等风险。（[accuray.com](https://www.accuray.com/company/)） Accuray 成立于 1990 年，其业务围绕 CyberKnife 和 TomoTherapy 这两个旗舰平台建立，此后通过 Radixact、Accuray Precision 治疗计划软件和 iDMS 数据管理工具扩展了其产品组合。该公司设计、制造、销售和维修放射治疗系统及相关软件，创建了一种将高价值系统部署与与已安装基础相关的经常性服务收入相结合的商业模式。这种组合具有战略重要性，因为它可以帮助平衡系统订单的波动性与随着时间推移更稳定的服务经济效益。（[accuray.com](https://www.accuray.com/company/)） 竞争定位以精度、自动化和临床多功能性为中心。Accuray 将其技术应用于肿瘤学和神经放射外科，并强调其能够精确治疗难以解决的肿瘤。该公司的全球足迹也是一个显著特征：制造工厂位于威斯康星州麦迪逊和中国成都，并在瑞士、日本、中国和香港设有区域办事处。这种国际存在支持了商业化，但也带来了供应链中断、关税、外汇波动和其他跨境运营风险的重大影响。（[accuray.com](https://www.accuray.com/company/)） 近期发展对投资案例至关重要。2025 年 8 月，Accuray 公布了 2025 财年第四季度和全年业绩，突出了服务收入增长、完成了债务再融资并发布了 2026 财年指引。管理层预计总净收入为 471 million 至 485 million 美元，调整后 EBITDA 为 31 million 至 35 million 美元。该公司还指出客户采用、产品组合扩展及其中国合资企业持续取得进展。对于跟踪 SEC Form 4 内部人交易活动的投资者而言，该名称属于小型医疗保健技术公司，其中运营执行、资产负债表管理和国际商业化都是关键的决定因素。（[investors.accuray.com](https://investors.accuray.com/news-releases/news-release-details/accuray-reports-fourth-quarter-and-fiscal-2025-financial-results)）
